Peptide antagonist of the androgen receptor

Current Pharmaceutical Design

Volumn 16, Issue 9, 2010, Pages 1106-1113

  Gao, Wenqing ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Androgen receptor; Peptide antagonist

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; HYDROXYFLUTAMIDE; PEPTIDE DERIVATIVE; SINTOKAMIDE A; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; TESTOSTERONE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG BINDING SITE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; LIGAND BINDING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; REVIEW;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANDROGEN ANTAGONISTS; ANIMALS; BINDING SITES; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; MODELS, STRUCTURAL; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN;

EID: 77950281942     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790963850     Document Type: Review

References (62)

1. Freedman LP. Molecular biology of steroid and nuclear hormone receptors. Boston: Birkhauser 1998.
2. th ed. Hoboken, N.J.: Wiley; 2003.
3. th ed. Philadelphia: Lippincott Williams & Wilkins 2002.
4. Singh SM, Gauthier S, Labrie F. Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem 2000; 7(2): 211-247
5. Gao W, Bohl CE, Dalton JT. Chemistry and structural biology of androgen receptor. Chem Rev 2005; 105(9): 3352-3370
6. Buijsman RC, Hermkens PH, van Rijn RD, Stock HT, Teerhuis NM. Non-steroidal steroid receptor modulators. Curr Med Chem 2005; 12(9): 1017-1075
7. Chen J, Kim J, Dalton JT. Discovery and therapeutic promise of selective androgen receptor modulators. Mol Interv 2005; 5(3): 173-188
8. Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem 2009; 52(12): 3597-3617
9. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, et al. Androgen receptor mutations in androgenindependent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003; 21(14): 2673-2678
10. Miyamoto H, Rahman MM, Chang C. Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 2004; 91(1): 3-12.
11. Gottlieb B, Lehvaslaiho H, Beitel LK, Lumbroso R, Pinsky L, Trifiro M. The androgen receptor gene mutations database. Nuclei Acid Res 1998; 26(1): 234-238
12. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996; 29(3): 153-158
13. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63(1): 149-153
14. Werner R, Holterhus PM, Binder G, Schwarz HP, Morlot M, Struve D, et al. The A645D mutation in the hinge region of the human androgen receptor (AR) gene modulates AR activity, depending on the context of the polymorphic glutamine and glycine repeats. J Clin Endocrinol Metabol 2006; 91(9): 3515-3520
15. McEwan IJ. Molecular mechanisms of androgen receptor-mediated gene regulation: structure-function analysis of the AF-1 domain. Endocr Relat Cancer 2004; 11(2): 281-293
16. Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT. Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci USA 2004; 101(14): 4758-4763
17. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 2005; 102(17): 6201-6206
18. Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem 2005; 280(45): 37747-37754
19. Bohl CE, Wu Z, Miller DD, Bell CE, Dalton JT. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligandinduced conformational changes and structure-based drug design. J Biol Chem 2007; 282(18): 13648-13655
20. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 2000; 275(34): 26164-26171
21. Ostrowski J, Kuhns JE, Lupisella JA, Manfredi MC, Beehler BC, Krystek SR, Jr, et al. Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology 2007; 148(1): 4-12.
22. Pereira de Jesus-Tran K, Cote PL, Cantin L, Blanchet J, Labrie F, Breton R. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci 2006; 15(5): 987-999
23. Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y, et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA 2001; 98(9): 4904-4909
24. Salvati ME, Balog A, Shan W, Wei DD, Pickering D, Attar RM, et al. Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists. Bioorg Med Chem Lett 2005; 15(2): 271-276
25. Sun C, Robl JA, Wang TC, Huang Y, Kuhns JE, Lupisella JA, et al. Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold. J Med Chem 2006; 49(26): 7596-7599
26. Wang F, Liu XQ, Li H, Liang KN, Miner JN, Hong M, et al. Structure of the ligand-binding domain (LBD) of human androgen receptor in complex with a selective modulator LGD2226. Acta Crystallog 2006; 62 (Pt 11): 1067-1071
27. Lavery DN, McEwan IJ. Structural characterization of the native NH2-terminal transactivation domain of the human androgen receptor: a collapsed disordered conformation underlies structural plasticity and protein-induced folding. Biochemistry 2008; 47(11): 3360-3369
28. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 1997; 18(3): 306-360
29. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002; 23(2): 175-200.
30. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002; 9(3): 601-610
31. Hur E, Pfaff SJ, Payne ES, Gron H, Buehrer BM, Fletterick RJ. Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol 2004; 2(9): E274.
32. Chawnshang C. Androgens and androgen receptor : mechanisms, functions, and clinical applications. Boston: Kluwer Academic Publishers 2002.
33. He B, Minges JT, Lee LW, Wilson EM. The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J Biol Chem 2002; 277(12): 10226-10235
34. Chang CY, McDonnell DP. Androgen receptor-cofactor interactions as targets for new drug discovery. Trends Pharmacol Sci 2005; 26(5): 225-228
35. Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D, et al. A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol 1996; 3(1): 87-94.
36. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997; 387(6634): 733-736
37. Bourguet W, Germain P, Gronemeyer H. Nuclear receptor ligandbinding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 2000; 21(10): 381-388
38. Pearce KH, Iannone MA, Simmons CA, Gray JG. Discovery of novel nuclear receptor modulating ligands: an integral role for peptide interaction profiling. Drug Discov Today 2004; 9(17): 741-751
39. Dubbink HJ, Hersmus R, Verma CS, van der Korput HA, Berrevoets CA, van Tol J, et al. Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor. Mol Endocrinol 2004; 18(9): 2132-2150
40. He B, Gampe RT, Jr, Kole AJ, Hnat AT, Stanley TB, An G, et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 2004; 16(3): 425-438
41. Warnmark A, Treuter E, Gustafsson JA, Hubbard RE, Brzozowski AM, Pike AC. Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha. J Biol Chem 2002; 277(24): 21862-21868
42. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389(6652): 753-758
43. Kauppi B, Jakob C, Farnegardh M, Yang J, Ahola H, Alarcon M, et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem 2003; 278(25): 22748-22754
44. Langley E, Kemppainen JA, Wilson EM. Intermolecular NH2-/carboxyl- terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J Biol Chem 1998; 273(1): 92-101.
45. Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM. Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol 1999; 13(3): 440-454
46. Hall JM, Chang CY, McDonnell DP. Development of peptide antagonists that target estrogen receptor -coactivator interactions. Mol Endocrinol 2000; 14(12): 2010-2023
47. McDonnell DP, Chang CY, Norris JD. Development of peptide antagonists that target estrogen receptor-cofactor interactions. J Steroid Biochem Mol Biol 2000; 74(5): 327-335
48. Chang CY, McDonnell DP. Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol Endocrinol 2002; 16(4): 647-660
49. Chang CY, Abdo J, Hartney T, McDonnell DP. Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. Mol Endocrinol 2005; 19(10): 2478-2490
50. Hsu CL, Chen YL, Yeh S, Ting HJ, Hu YC, Lin H, et al. The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs. J Biol Chem 2003; 278(26): 23691-23698
51. Sathya G, Chang CY, Kazmin D, Cook CE, McDonnell DP. Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. Cancer Res 2003; 63(22): 8029-8036
52. Reid J, Kelly SM, Watt K, Price NC, McEwan IJ. Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation. Influence of structure-stabilizing solutes and protein-protein interactions. J Biol Chem 2002; 277(22): 20079-20086
53. Davies P, Watt K, Kelly SM, Clark C, Price NC, McEwan IJ. Consequences of poly-glutamine repeat length for the conformation and folding of the androgen receptor amino-terminal domain. J Mol Endocrinol 2008; 41(5): 301-314
54. Callewaert L, Van Tilborgh N, Claessens F. Interplay between two hormone-independent activation domains in the androgen receptor. Cancer Res 2006; 66(1): 543-553
55. Quayle SN, Mawji NR, Wang J, Sadar MD. Androgen receptor decoy molecules block the growth of prostate cancer. Proc Natl Acad Sci USA 2007; 104(4): 1331-1336
56. Sadar MD, Williams DE, Mawji NR, Patrick BO, Wikanta T, Chasanah E, et al. Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the Nterminus of the androgen receptor in prostate cancer cells. Org Lett 2008; 10(21): 4947-4950
57. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007; 28(7): 778-808.
58. Stolnik S, Shakesheff K. Formulations for delivery of therapeutic proteins. Biotechnol Lett 2009; 31(1): 1-11.
59. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006; 103(16): 6315-6320
60. Bortolato A, Mobarec JC, Provasi D, Filizola M. Progress in elucidating the structural and dynamic character of G Protein-Coupled Receptor oligomers for use in drug discovery. Curr Pharm Des 2009; 15(35): 4017-4025
61. de Graaf C, Rognan D. Customizing G Protein-coupled receptor models for structure-based virtual screening. Curr Pharm Des 2009; 15(35): 4026-4048
62. Hospers GA, Helmond FA, de Vries EG, Dierckx RA, de Vries EF. PET imaging of steroid receptor expression in breast and prostate cancer. Curr Pharm Des 2008; 14(28): 3020-3032